Manufacturing questions for Fosun subsidiary resurface

A second manufacturing scandal in as many weeks involving alleged falsification of manufacturing records drove down shares of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) on Friday. According to

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE